Zimmer Biomet’s (ZBH) “Hold” Rating Reiterated at Truist Financial

Truist Financial reaffirmed their hold rating on shares of Zimmer Biomet (NYSE:ZBH) in a research report report published on Monday morning,Benzinga reports. Truist Financial currently has a $113.00 target price on the medical equipment provider’s stock, down from their previous target price of $118.00.

A number of other equities research analysts also recently issued reports on the stock. Wells Fargo & Company increased their price target on shares of Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st. Oppenheimer lowered their price objective on Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 15th. Barclays reduced their target price on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a research report on Monday. Raymond James lowered their price target on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating on the stock in a report on Friday, February 7th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a report on Friday, February 7th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat, Zimmer Biomet currently has a consensus rating of “Hold” and a consensus target price of $124.15.

Zimmer Biomet Stock Performance

Shares of ZBH stock opened at $98.98 on Monday. The firm’s 50 day moving average is $106.91 and its 200 day moving average is $107.91. The stock has a market capitalization of $19.70 billion, a P/E ratio of 22.24, a PEG ratio of 1.83 and a beta of 1.02. Zimmer Biomet has a 12 month low of $97.69 and a 12 month high of $133.90. The company has a current ratio of 1.91, a quick ratio of 0.70 and a debt-to-equity ratio of 0.43.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter in the prior year, the company earned $2.20 EPS. On average, sell-side analysts anticipate that Zimmer Biomet will post 8.25 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Monday, December 30th were issued a dividend of $0.24 per share. The ex-dividend date was Monday, December 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.97%. Zimmer Biomet’s dividend payout ratio is presently 21.57%.

Institutional Trading of Zimmer Biomet

Institutional investors and hedge funds have recently bought and sold shares of the stock. Stonebridge Financial Group LLC bought a new position in shares of Zimmer Biomet during the fourth quarter valued at approximately $25,000. Dunhill Financial LLC increased its position in Zimmer Biomet by 1,090.0% during the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after buying an additional 218 shares in the last quarter. Ashton Thomas Securities LLC purchased a new position in Zimmer Biomet during the third quarter valued at $28,000. Brooklyn Investment Group bought a new stake in Zimmer Biomet in the third quarter worth $35,000. Finally, Kentucky Trust Co purchased a new stake in shares of Zimmer Biomet in the fourth quarter worth $39,000. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.